CTNM

Contineum Therapeutics, Inc. Class A Common Stock

Insider Trades

Name	Value	Action	Price	Current Price
Lorrain Daniel S.Chief Scientific Officer $55k4.2k shares SellJun 1, 2026 $13.16 --
Lorrain Daniel S.Chief Scientific Officer $4.2k300 shares SellMay 1, 2026 $13.84 --
Lorrain Daniel S.Chief Scientific Officer $51k3.9k shares SellMay 1, 2026 $13.06 --
Lorrain Daniel S.Chief Scientific Officer $56k4.2k shares SellApr 6, 2026 $13.43 --
Lorrain Daniel S.Chief Scientific Officer $63k4.2k shares SellMar 2, 2026 $15.01 --
Watkins TimCMO & Head Of Development $54k3.6k shares SellMar 2, 2026 $15.02 --

News

businesswire.comContineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conferencebusinesswire.comJun 1

zacks.comWall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?zacks.comMay 25

marketbeat.comContineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potentialmarketbeat.comMay 22

businesswire.comContineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)businesswire.comMay 15

businesswire.comContineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conferencebusinesswire.comMay 12

Trade CTNM

About Contineum Therapeutics, Inc. Class A Common Stock

Contineum Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise, dedicated to the discovery and advancement of innovative oral small molecule therapies. Their primary focus lies in addressing neurological, inflammatory, and immunological disorders characterized by significant unmet medical needs. The company's foremost therapeutic candidate is PIPE-791, a pioneering, brain-penetrant small molecule designed to inhibit the lysophosphatidic acid 1 receptor (LPA1R). This compound is currently being investigated for its potential in treating idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). Additionally, Contineum is developing PIPE-307, a novel small molecule functioning as a selective inhibitor of the muscarinic type 1 M1 receptor, intended for the management of depression and relapse-remitting MS. Another asset in their pipeline is CTX-343, an LPA1R antagonist with activity restricted to the periphery. Founded in 2009, this San Diego, California-headquartered organization was formerly known as Pipeline Therapeutics, Inc. before officially changing its name to Contineum Therapeutics, Inc. in November 2023.

CEO: Carmine N. Stengone
IPO Date: Apr 5, 2024

Market Data

Open: $12.39
High: $12.67
Low: $11.57
Volume: 313.9K
Avg Volume: 260.2K
52W High: $16.33
52W Low: $3.69

Valuation

Market Cap: $446M
Enterprise Value: $433M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-56M
Revenue: $0
Net Income: $-60M
Cash: $76M
Debt: $8.3M

Events

EarningsAug 4

EPS est. -0.46